ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01013506
Recruitment Status : Withdrawn (Study was abandoned before opening to accrual. Replaced by another study.)
First Posted : November 13, 2009
Last Update Posted : May 23, 2013
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ingrid Mayer, MD, Vanderbilt-Ingram Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : December 2009
  Actual Study Completion Date : December 2009